JP2024081718A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024081718A5 JP2024081718A5 JP2024049655A JP2024049655A JP2024081718A5 JP 2024081718 A5 JP2024081718 A5 JP 2024081718A5 JP 2024049655 A JP2024049655 A JP 2024049655A JP 2024049655 A JP2024049655 A JP 2024049655A JP 2024081718 A5 JP2024081718 A5 JP 2024081718A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- amino acid
- seq
- nos
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862646053P | 2018-03-21 | 2018-03-21 | |
| US62/646,053 | 2018-03-21 | ||
| PCT/US2019/023382 WO2019183362A1 (en) | 2018-03-21 | 2019-03-21 | Fc variant compositions and methods of use thereof |
| JP2020550791A JP7551499B2 (ja) | 2018-03-21 | 2019-03-21 | Ｆｃバリアント組成物およびその使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020550791A Division JP7551499B2 (ja) | 2018-03-21 | 2019-03-21 | Ｆｃバリアント組成物およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024081718A JP2024081718A (ja) | 2024-06-18 |
| JP2024081718A5 true JP2024081718A5 (enExample) | 2024-10-15 |
| JP7804715B2 JP7804715B2 (ja) | 2026-01-22 |
Family
ID=67988040
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020550791A Active JP7551499B2 (ja) | 2018-03-21 | 2019-03-21 | Ｆｃバリアント組成物およびその使用方法 |
| JP2024049655A Active JP7804715B2 (ja) | 2018-03-21 | 2024-03-26 | Ｆｃバリアント組成物およびその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020550791A Active JP7551499B2 (ja) | 2018-03-21 | 2019-03-21 | Ｆｃバリアント組成物およびその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20210070860A1 (enExample) |
| EP (1) | EP3768315A4 (enExample) |
| JP (2) | JP7551499B2 (enExample) |
| AU (1) | AU2019240247B2 (enExample) |
| WO (1) | WO2019183362A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2998174A1 (en) * | 2015-09-15 | 2017-03-23 | Amgen Inc. | Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| CA3173944A1 (en) | 2021-01-13 | 2022-07-21 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
| CN113061192B (zh) * | 2021-04-12 | 2023-08-22 | 佰思巢(上海)生物科技有限公司 | 一类对pd-1受体具有高亲和力的pdl1融合蛋白及其作为t细胞抑制剂的应用 |
| CN115873126A (zh) * | 2021-11-26 | 2023-03-31 | 深圳科兴药业有限公司 | 人生长激素融合蛋白及其制备和用途 |
| AU2023324669A1 (en) | 2022-08-15 | 2025-02-13 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
| EP4572785A1 (en) | 2022-08-15 | 2025-06-25 | Dana-Farber Cancer Institute, Inc. | Antibodies against cldn4 and methods of use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL209392B1 (pl) * | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| CN102549016B (zh) * | 2009-06-30 | 2015-05-06 | 研究发展基金会 | 免疫球蛋白fc多肽 |
| DK2516468T3 (en) * | 2009-12-23 | 2016-05-23 | Synimmune Gmbh | ANTI-FLT3 ANTIBODIES AND METHODS FOR USING THESE |
| US8952132B2 (en) * | 2011-02-07 | 2015-02-10 | Research Development Foundation | Engineered immunoglobulin FC polypeptides |
| US9028826B2 (en) * | 2011-04-04 | 2015-05-12 | The Trustees Of Dartmouth College | Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties |
| TWI687439B (zh) * | 2011-06-30 | 2020-03-11 | 中外製藥股份有限公司 | 異源二聚化多胜肽 |
| US10011660B2 (en) * | 2012-04-30 | 2018-07-03 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| CN104736174B (zh) * | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| WO2016033509A1 (en) * | 2014-08-29 | 2016-03-03 | The Regents Of The University Of Colorado, A Body Corporate | Aquaporin-4 antibodies and uses thereof for the treatment of neuromyelitis optica |
| EP3191519A1 (en) * | 2014-09-12 | 2017-07-19 | Biogen MA Inc. | Humanized anti-alpha v beta 5 antibodies and uses thereof |
| BR112017013981A2 (pt) * | 2015-01-26 | 2018-01-02 | Cellectis | receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer |
| AU2016227632A1 (en) * | 2015-03-05 | 2017-09-14 | Ucb Biopharma Sprl | Polymeric Fc proteins and methods of screening to alter their functional characteristics |
| KR20180002653A (ko) * | 2015-04-07 | 2018-01-08 | 제넨테크, 인크. | 효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법 |
| BR112019001262A2 (pt) * | 2016-07-22 | 2019-05-07 | Dana-Farber Cancer Institute, Inc. | anticorpos para o receptor do fator de necrose de tumor induzido por glicocorticoide (gitr) e métodos de uso dos mesmos |
| WO2018027204A1 (en) * | 2016-08-05 | 2018-02-08 | Genentech, Inc. | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
-
2019
- 2019-03-21 US US16/982,723 patent/US20210070860A1/en active Pending
- 2019-03-21 JP JP2020550791A patent/JP7551499B2/ja active Active
- 2019-03-21 EP EP19771823.2A patent/EP3768315A4/en active Pending
- 2019-03-21 WO PCT/US2019/023382 patent/WO2019183362A1/en not_active Ceased
- 2019-03-21 AU AU2019240247A patent/AU2019240247B2/en active Active
-
2024
- 2024-02-06 US US18/434,536 patent/US20250066481A1/en active Pending
- 2024-03-26 JP JP2024049655A patent/JP7804715B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024081718A5 (enExample) | ||
| JP2023036899A5 (enExample) | ||
| US11382963B2 (en) | Engineered T cells and uses therefor | |
| WO2020047299A1 (en) | Multi-chain chimeric polypeptides and uses thereof | |
| US20210077576A1 (en) | Combination tumor treatment with an integrin-binding-fc fusion protein and immune stimulator | |
| CN116171167B (zh) | 包含配体-受体对和生物功能蛋白的融合蛋白 | |
| RU2018108236A (ru) | Слитые белки на основе gitrl и пути их применения | |
| US10350266B2 (en) | Method of treating cancer with a multiple integrin binding Fc fusion protein | |
| EP3988577A1 (en) | Anti-cd137 antibodies | |
| Müller et al. | A novel antibody–4-1BBL fusion protein for targeted costimulation in cancer immunotherapy | |
| JP2018522571A5 (enExample) | ||
| US20210015870A1 (en) | Bcma-car-t cells | |
| JP2020505054A5 (enExample) | ||
| JP2018524326A5 (enExample) | ||
| JP2024504728A5 (enExample) | ||
| CN114302891A (zh) | 新的il-10变体蛋白及其用途 | |
| JP2024539630A5 (enExample) | ||
| CN109897114A (zh) | 具有自杀基因开关的靶向cd47的工程化免疫细胞 | |
| WO2023079102A2 (en) | Novel peptides | |
| CA3220872A1 (en) | Antibody-nkg2d ligand domain fusion protein | |
| US12528873B2 (en) | Humanized BCMA antibody and BCMA-CAR-T cells | |
| WO2020112529A1 (en) | Car-t cells having humanized cd19 scfv with mutation in cdr 1 region | |
| CA3220875A1 (en) | Antibody-nkg2d ligand domain fusion protein | |
| KR20250096834A (ko) | 융합 단백질 및 이의 용도 | |
| CN120225665A (zh) | 包含nkg2d、cxcr2和dap10/dap12融合多肽的组合物及其使用方法 |